| Code | CSB-RA723415MB13HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Sym-024, targeting NT5E (ecto-5'-nucleotidase), also known as CD73. NT5E is an ectoenzyme anchored to the cell surface that catalyzes the conversion of extracellular adenosine monophosphate (AMP) to adenosine, a potent immunosuppressive molecule. By generating adenosine in the tumor microenvironment, NT5E contributes to immune evasion by suppressing T cell and natural killer cell activity while promoting regulatory T cell function. Elevated NT5E expression is associated with poor prognosis in multiple cancer types, including triple-negative breast cancer, ovarian cancer, melanoma, and colorectal cancer, making it an important target in immuno-oncology research.
Sym-024 is a clinical-stage therapeutic antibody designed to block NT5E enzymatic activity and disrupt adenosine-mediated immunosuppression in tumors. This biosimilar provides researchers with a valuable tool for investigating adenosine pathway mechanisms, studying immune checkpoint modulation, and exploring combination immunotherapy strategies. It enables detailed examination of NT5E's role in tumor progression, metastasis, and resistance to cancer therapies in preclinical models.
There are currently no reviews for this product.